A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women

CONCLUSIONS: Vaccine formulations containing PTgen were safe and immunogenic in pregnant women. The ap1gen vaccine, with the lowest cost and reactogenicity, may be suitable for use in pregnant women when diphtheria and tetanus toxoids are not needed. This study is registered in the Thai Clinical Trial Registry (www.CLINICALTRIALS: in.th), number TCTR20180725004.PMID:37330371 | DOI:10.1016/j.vaccine.2023.06.001

Source: Vaccine - June 17, 2023 Category: Allergy & Immunology Authors: Thanyawee Puthanakit Kulkanya Chokephaibulkit Surasith Chaithongwongwatthana Niranjan Bhat Yuxiao Tang Suvaporn Anugulruengkitt Chenchit Chayachinda Sanitra Anuwutnavin Keswadee Lapphra Supattra Rungmaitree Monta Tawan Indah Andi-Lolo Renee Holt Librada F Source Type: research